• Regulatory Consulting

  • Registration & Listing

  • Call 619-517-0673

By - SebastianFeye

How to fight the coronavirus SARS-CoV-2 and its disease, COVID-19 – Michael Lin, PhD-MD

A very informative and detailed overview of the SARS-CoV-2 or novel Coronavirus from a Stanford Doctor, Michael Lin, as well as a bonus recipe at end for making hand sanitizer. Links referenced in Slides Slide 3: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm Slide 4: https://abcnews.go.com/Health/covid19-days-surfaces-experiment-findings/story%3Fid=69569397 Slide 5: https://www.vox.com/2020/2/14/21135208/coronavirus-wuhan-china-covid-19-name-sars-cov-2 Slide 6: https://www.ncbi.nlm.nih.gov/pubmed/31971553, https://www.ncbi.nlm.nih.gov/pubmed/15280490 Slide 7: http://doi.org/10.1101/2020.03.09.20033217, https://www.ncbi.nlm.nih.gov/pubmed/22312351 Slide 8: https://en.wikipedia.org/wiki/2020_coronavirus_pandemic_in_South_Korea, https://wwwnc.cdc.gov/eid/article/26/6/20-0320_article, https://www.worldometers.info/coronavirus/country/south-korea/ Slide 9: https://cmmid.github.io/topics/covid19/severity/diamond_cruise_cfr_estimates.html, http://www.wsj.com/articles/experimental-drug-helps-some-americans-ride-out-coronavirus-nih-doctor-says-11584094955,

By - SebastianFeye

CBD – To Be or Not to Be a Drug? Predicting the Impending FDA Regulations on Cannabis.

This blog post was written following a ReedTech webinar (dated 11.7.2019) which focused on helping companies understand how to navigate the state of Cannabidiol (CBD) regulatory environment. This post is for informative purposes only and to provide guidance to minimize risks when labeling, promoting and selling cannabis-derived products in the US. To date, FDA has approved only one CBD drug